IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Anthony FUTERMAN et al

Serial No.:

10/552,287

Filed:

January 04, 2007

For:

GAUCHER DISEASE DRUGS AND

METHODS OF IDENTIFYING SAME

Examiner:

STEADMAN, DAVID J

Group Art Unit: 1656

Attorney

\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$

Docket: 30227

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Supplemental Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin D. Moynihan Registration No. 40,338

Dated: April 21, 2008